This bill establishes a psilocybin therapeutic use program in Minnesota, allowing individuals aged 21 and older with qualifying medical conditions to access psilocybin under the supervision of registered facilitators. It creates a legal framework that includes definitions, eligibility criteria, and the roles of participants such as patients, facilitators, suppliers, and testing facilities. The commissioner of health will administer the program, which involves rulemaking, data collection, and collaboration with an advisory committee. Key provisions include a secure registration system for tracking patients, health screenings, informed consent requirements, and guidelines for psilocybin cultivation and testing. The bill also protects registered participants from civil or criminal penalties related to their involvement in the program and mandates a program evaluation after three years.

Additionally, the bill amends the classification of psilocybin by removing it from the Schedule I controlled substances list, facilitating its therapeutic use. It introduces provisions for data privacy, ensuring that submitted data remains confidential, and establishes a fee structure for program participants, with reduced fees for those on disability benefits. The bill also clarifies the status of peyote in relation to its use in religious ceremonies for the American Indian Church, while requiring manufacturers and distributors to comply with federal registration. Furthermore, it adds a new category for hallucinogens in Schedule IV, recognizing substances like psilocybin and psilocin as controlled substances unless exempted.

Statutes affected:
1st Engrossment: 152.02